Shares of the company are trading at $20.04 slightly over the 50 day moving average which is $18.95 and quite a bit higher than the 200 day moving average of $15.93. The 50 day moving average went up $1.09 or +5.77% whereas the 200 day moving average was up $4.11 or +25.81%. Trading volume for CytomX Therapeutics, Inc. was 254K in the last trading session. Trading volume was up 63.07% over the stocks average daily volume.
Investors are a little more bearish on the company if you take note of the motion in short interest. The company had a rise in short interest of 26.68% as of the latest report on September 29, 2017. Short interest increased from 1,216,204 to 1,540,738 over that timeframe. The short-interest ratio increased to 7.0 and the percentage of shorted shares was 0.04% on September 29.
CytomX Therapeutics, Inc. (NASDAQ:CTMX) has been the object of insider selling activity recently. CSO, Head Res.&Non-Clin. Dev. William Michael Kavanaugh sold 48,368 shares at an average price of $24.34 on October 4th. Kavanaugh now owns $338,740 of stock as recorded in a recent Form 4 SEC filing. Director Frederick W. Gluck let go of 10,000 shares at an average price of $24.27 on Wed the 4th. That brings Gluck’s holdings to $7,563,576 per an SEC filing yesterday.
Sean A. Mccarthy, President and CEO disclosed the sale of 19,120 shares of CTMX stock. The shares were purchased at an average price of $24.13. The President and CEO now owns $102,432 of the stock according to the SEC filing.
A few notable investment firms have updated their holdings. As of the end of the quarter Vident Investment Advisory, LLC had bought a total of 7,468 shares growing its stake by 9.8%. The value of the company’s investment in CytomX Therapeutics, Inc. went from $1,311,000 to $1,293,000 a change of $18,000 for the reporting period. Opaleye Management Inc. expanded its stake by buying 120,000 shares an increase of 35.3% from 03/31/2017 to 06/30/2017. Opaleye Management Inc. controls 460,000 shares with a value of $7,130,000. The value of the position overall is up by 21.4%.
Acadian Asset Management LLC cut its position by selling 2,524 shares a decrease of 61.1% as of 09/30/2017. Acadian Asset Management LLC owns 1,608 shares worth $29,000. The total value of its holdings decreased 54.7%. As of quarter end Meeder Asset Management Inc had acquired 433 shares growing its position 155.8%. The value of the investment in CytomX Therapeutics, Inc. increased from $4,000 to $13,000 a change of 225.0% quarter over quarter.
Equity analyst Wedbush began coverage giving it an initial rating of “Outperform”.
As of the last earnings report the EPS was $-1.70 and is expected to be $-1.47 for the current year with 36,867,000 shares presently outstanding. Next quarter’s EPS is forecasted to be $-0.41 and the next full year EPS is projected to be $-1.38.
CytomX Therapeutics, Inc., launched on September 16, 2010, is a clinical-stage, oncology-focused biopharmaceutical company. The Company uses its Probody technology platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against difficult-to-drug targets. Its pipeline is focused on the development of therapies in a set of modalities: Probody cancer immunotherapies, probody drug conjugates (PDCs), T-cell engaging Probody bispecifics and ProCAR-NK cell therapies. Its product candidates include CX-072, CX-2009, CX-2029, Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and CX-188. Its Probody platform utilizes active proteases in tumor tissue to allow monoclonal antibody-based therapies to be delivered in an inactive state and then to be activated at the tumor site..